SHENIKA GARNER: Open Payments
NPI 1104315183 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,640 in 65 payments from 28 companies in 2025. Trend: 2023 $711 · 2024 $1,152 · 2025 $1,640
Food & beverage: $1,640
| Company | Payments | Amount |
|---|---|---|
| Eisai Inc. | 6 | $282 |
| Merck Sharp & Dohme LLC | 8 | $184 |
| Daiichi Sankyo Inc. | 8 | $179 |
| Janssen Biotech, Inc. | 7 | $166 |
| AstraZeneca Pharmaceuticals LP | 5 | $137 |
| GlaxoSmithKline, LLC. | 6 | $122 |
| Genentech USA, Inc. | 3 | $62 |
| ABBVIE INC. | 2 | $37 |
| Ethicon US, LLC | 1 | $35 |
| Invivyd Inc | 1 | $32 |
Products named: Lenvima, KEYTRUDA, RYBREVANT, Enhertu, JEMPERLI, Polivy, LYNPARZA, DATROWAY.
Industry payments across GA — which companies pay providers there.
